Avatrombopag

Chemical formula: C₂₉H₃₄Cl₂N₆O₃S₂  Molecular mass: 649.65 g/mol  PubChem compound: 9852519

Therapeutic indications

Avatrombopag is indicated for:

Severe thrombocytopenia with chronic liver disease

Population group: only adults (18 - 65 years old)

Avatrombopag is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Primary chronic immune thrombocytopenia (ITP)

Population group: only adults (18 - 65 years old)

Avatrombopag is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2021: DOPTELET Film-coated tablet
Structured Product Labeling (SPL/PLR) 2020: DOPTELET Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈